By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring Release: Many Rare Disease Patients Would Not Have Treatments Available To Them Without An Adequate Supply Of Human Plasma 10/10/2016 7:44:05 AM
FDA Accepts CSL Behring's Biologics License Application For First Subcutaneous Prophylactic Therapy To Prevent Hereditary Angioedema Attacks 8/30/2016 8:00:02 AM
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress 7/27/2016 8:17:50 AM
CSL Behring Presents Phase III Data For IDELVION For Hemophilia B At The World Federation of Hemophilia 2016 World Congress 7/26/2016 8:26:49 AM
CSL Behring Awards Emerging Coagulation Specialists Across The Globe To Support Advancements In The Care Of Patients With Bleeding Disorders 7/25/2016 10:25:16 AM
CSL Behring To Present New Data For IDELVION And AFSTYLA At The World Federation of Hemophilia 2016 World Congress 7/19/2016 8:32:57 AM
U.S. FDA Approves CSL Behring's Berinert As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE) 7/18/2016 12:23:23 PM
CSL Behring Announces Immunoglobulin Research Grant Winners 6/23/2016 7:23:10 AM
AFSTYLA - CSL Behrings Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S. 6/20/2016 7:23:34 AM
CMC Biologics Cleared For Commercial Manufacture Of CSL Behring's FDA-Approved AFSTYLA 6/15/2016 11:08:02 AM